Push/Pull

REVAMP, a pull incentive in the US: Time to make it happen!

Dear All: I previously wrote about the nascent REVAMP legislation that would create a Pull incentive in the US market. With everybody back from the July 4th holiday, the goal for this week is to get REVAMP into position to be offered as an amendment at the House Energy & Commerce Committee’s PAHPA mark-up (expected next week).

Read More »

Heads-up on REVAMP, a credible Pull incentive for the US!

Dear All: Incredibly exciting news! Due to the bipartisan efforts of Representatives John Shimkus (R-IL) and Tony Cardenas (D-CA), the Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 is now being introduced. This is the Pull incentive that we’ve been looking for in the US! The very short summary is that REVAMP (a) creates a new “priority antimicrobial product” category, (b) grants

Read More »

Incentives for antibiotics: Recent papers, with an emphasis on Pull

Dear All:  For your weekend reading list, I have some papers on the topic of (mostly pull) incentives for antibiotics. First, I previously wrote about the survey from TATFAR (Transatlantic Task Force on Antimicrobial Resistance) of 6 possible pull models (higher reimbursement, diagnostic confirmation, market entry rewards both fully and partially delinked, tradable exclusivity vouchers, and an options market).

Read More »

WHO-FAO-OIE-UNEP survey on a multi-stakeholder AMR platform

Dear All (this newsletter experiments with an Executive Summary/Details format; let me know what you think),  (Executive Summary)  As a further support for implementation of recommendations from the UN Interagency Coordination Group on Antimicrobial Resistance (IACG AMR), the Tripartite Plus (WHO-FAO-OIE-UNEP) are seeking to create a Partnership Platform that will “engage institutions representing states, markets and

Read More »

Ex-US new antibiotic access: Multi-year delays, even in Europe!

Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), Post-newsletter addendum: A slide deck that summarizes the data from the paper is now available. We talked in a 22 Mar 2021 newsletter about ensuring access to new antibiotics and you should take a moment to refresh your memory of its discussions of

Read More »

Pull incentives in the EU / Statements by Commissioner Kyriakides

Dear All (and note the related 28 Nov 2020 newsletter), Stella Kyriakides, the European Commissioner for Health and Food Safety, made some really interesting statements before the European Parliament’s health committee (ENVI) on Thursday of last week (22 April). Per this Exchange of Views on the EP’s multimedia center and this news report, here are some

Read More »

Outstanding discussions of Pull, the NHS Pilot, and Antibiotic value

Dear All, The BEAM Alliance, along with its partners (CARB-X, the Novo REPAIR Impact Fund, the IMI AMR Accelerator, and the European Biotechnology Magazine) converted their annual AMR conference into a virtual event held 24-26 Aug 2021. As usual, it was excellent! I know we’re all really, REALLY tired of virtual meetings but the 2h/day x 3 day themed format worked well:

Read More »

“Astonishing mismatch”: Market potential of AMR tools vs. patient needs

Dear All, We have today an excellent report from the Global AMR R&D Hub entitled “Estimating Global Patient Needs and Market Potential for Priority Health Technologies Addressing Antimicrobial Resistance.” Both the bottom line and the key message of the report are clearly stated in the Preface: “… we hope that by showing the astonishing mismatch

Read More »

Beyond Pull: Maximizing availability + (appropriate!) use / Help needed!

Dear All, Today we have two interwoven topics to consider: An analysis of research priorities (not all technical!) and a triad of related initiatives, each of which comes with an opportunity for you to starting working on some of those priorities! First up, we have an excellent new paper summarizing the perspective of 32 experts

Read More »
Scroll to Top